Association Briefs

Biotech And The President's Budget Despite President Bush's fiscal 1991 budget request of $3.6 billion for biotechnology research and development, a 6% increase over 1990, the Industrial Biotechnology Association is displeased by at least one aspect of the plan. The thorn in the side of the IBA is the budget's inclusion of a U.S. Food and Drug Administration user fee, which would be assessed to any company applying for a product review. The budget calls for these fees to provide the FDA with $

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Biotech And The President's Budget
Despite President Bush's fiscal 1991 budget request of $3.6 billion for biotechnology research and development, a 6% increase over 1990, the Industrial Biotechnology Association is displeased by at least one aspect of the plan.

The thorn in the side of the IBA is the budget's inclusion of a U.S. Food and Drug Administration user fee, which would be assessed to any company applying for a product review. The budget calls for these fees to provide the FDA with $157 million in 1991. IBA President Richard D. Godown, who last year testified against such a fee before the House Appropriations Committee's Subcommittee on Rural Development, Agriculture, and Related Agencies, says that a user fee would likely suppress future product R&D by increasing new drug development costs. Godown believes the fees would be especially burdensome to small biotechnology companies.

Overall, however, Godown characterized the president's budget as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies